A share price of Palisade Bio Inc [PALI] is currently trading at $2.20, up 15.79%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PALI shares have gain 31.74% over the last week, with a monthly amount glided 6.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Palisade Bio Inc experienced fluctuations in its stock price throughout the past year between $1.38 and $22.35. Currently, Wall Street analysts expect the stock to reach $1.5 within the next 12 months. Palisade Bio Inc [NASDAQ: PALI] shares were valued at $2.20 at the most recent close of the market. An investor can expect a potential drop of -31.82% based on the average PALI price forecast.
Analyzing the PALI fundamentals
Gross Profit Margin for this corporation currently stands at 1.22% with Operating Profit Margin at 59.07%, Pretax Profit Margin comes in at 56.26%, and Net Profit Margin reading is 56.26%. To continue investigating profitability, this company’s Return on Assets is posted at -1.51, Equity is -1.48 and Total Capital is -2.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8400 points at the first support level, and at 1.4800 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.5000, and for the 2nd resistance point, it is at 2.8000.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Palisade Bio Inc [NASDAQ:PALI] is 3.28. As well, the Quick Ratio is 3.28, while the Cash Ratio is 3.0.
Transactions by insiders
Recent insider trading involved Williams Donald Allen, Director, that happened on May 28 ’24 when 1000.0 shares were purchased. CEO, CFO, Director, Finley John David completed a deal on May 24 ’24 to buy 1000.0 shares. Meanwhile, CEO, CFO, Director Finley John David bought 10000.0 shares on Feb 06 ’24.
